Where is Vasgen located?

Vasgen is headquartered in London, United Kingdom. It is registered at 1A STRATHEARN ROAD,WIMBLEDON,LONDON,SW19 7LH.

Who is the current CEO of Vasgen?

Salman Rahman of Vasgen. They have also founded 1 company.

How many employees does Vasgen have?

As of May 31, 2026, the latest employee count at Vasgen is 3.

Is Vasgen a funded company?

Vasgen is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Vasgen rank among its competitors?

Vasgen ranks 1849th amongst 3374 active competitors, of which 1156 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Vasgen?

Vasgen's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Vasgen - 2026 Company Profile, Team, Competitors & Financials

Vasgen is an unfunded company based in London (United Kingdom), founded in 2011 by Salman Rahman and Yatin Patel. It operates as a Developer of targeted antibody therapeutics for ophthalmology and cancer applications. Vasgen has not raised any funding yet. The company has 3374 active competitors, including 1156 funded and 794 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.

Company Details

Developer of targeted antibody therapeutics for ophthalmology and cancer applications. The company focuses on creating therapeutic solutions for unmet clinical needs. It applies a technology that uses targeted antibodies as inhibitors of metalloproteinase activity. The company’s research and development programme validates metalloproteinases of therapeutic interest.

Website: vasgen.co.uk
Email ID: *****@vasgen.co.uk
Phone Number: +44 **********
Registered Address: 1A STRATHEARN ROAD,WIMBLEDON,LONDON,SW19 7LH

Key Metrics

Founded Year

2011

Location

London, United Kingdom

Stage

Unfunded

Ranked

1849^th among 3374 active competitors

Employee Count

3 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3085 more

View Vasgen's full profile

Vasgen is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VASGEN LIMITED CIN: 7698573 , United Kingdom, Active	Jul 07, 2011	-	2 (As on Jul 31, 2023)

Vasgen has not raised any funding rounds yet.

The founders of Vasgen are Salman Rahman and Yatin Patel. Salman Rahman is the CEO of Vasgen.

Here are the details of Vasgen's key team members:

Salman Rahman: Co-Founder & CEO of Vasgen.
Yatin Patel: Co-Founder of Vasgen.

View details of Vasgen's Founder profiles and Board Members

Vasgen's employee count trend

Vasgen has 3 employees as of May 26. Here is Vasgen's employee count trend over the years:

Uncover Vasgen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vasgen include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Vasgen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
1849th	Vasgen 2011, London (United Kingdom), Unfunded	Developer of targeted antibody therapeutics for ophthalmology and cancer applications	-	-	30/100